Found: 2
Select item for more details and to access through your institution.
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 531, p. 1, doi. 10.1126/scitranslmed.aax2625
- By:
- Publication type:
- Article
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.
- Published in:
- Frontiers in Genetics, 2014, v. 5, p. 1, doi. 10.3389/fgene.2014.00152
- By:
- Publication type:
- Article